Differences in gene expression profiles of diabetic and nondiabetic patients undergoing cardiopulmonary bypass and

Pierre Voisine1, Marc Ruel, Tanveer A Khan

  • 1Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA.

Circulation
|September 15, 2004
PubMed

Insights

Diabetes significantly alters cardiac gene expression after heart surgery. These findings highlight distinct molecular responses in diabetic patients undergoing cardiopulmonary bypass (CPB) and cardioplegic arrest (C).

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Gene Expression Analysis

Background:

  • Diabetes mellitus is a significant risk factor for adverse outcomes following coronary artery bypass grafting (CABG).
  • Understanding the impact of cardiopulmonary bypass (CPB) and cardioplegic arrest (C) on cardiac gene expression is crucial for patient management.

Purpose of the Study:

  • To compare cardiac gene expression profiles in diabetic versus non-diabetic patients after CPB and C during CABG.
  • To identify specific genes and pathways affected by CPB/C in the context of diabetes.

Main Methods:

  • Atrial myocardium samples were collected from diabetic and non-diabetic patients before and after CPB/C.
  • Oligonucleotide microarrays analyzed the expression of 12,625 genes.
  • Array results were validated using Northern blotting and immunoblotting.

Main Results:

  • Diabetic patients exhibited a distinct gene expression profile post-CPB/C, with 851 upregulated and 480 downregulated genes, compared to non-diabetic patients (480 upregulated, 626 downregulated).
  • Several inflammatory, apoptotic, and stress-related genes were significantly upregulated in both groups.
  • A unique set of 28 genes, including those involved in inflammation and glucose metabolism, were exclusively upregulated in diabetic patients.

Conclusions:

  • The gene expression response to CPB/C differs quantitatively and qualitatively between diabetic and non-diabetic individuals.
  • These findings underscore the need for personalized myocardial protection strategies in diabetic patients undergoing cardiac surgery.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...